Hospital
Braxton County Memorial Hospital
Braxton County Memorial Hospital was paid $4.93M by Medicaid between Jan 2018 and Nov 2024, across 92 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoBRAXTON COUNTY MEMORIAL HOSPITAL
GASSAWAY, WV 26624
GASSAWAY, WV 26624
33aNPI1356304547assigned 04/10/2006
33bProvider typeCritical Access Hospital
28Total paid$4.93M
24GClaims78,434
24DCodes billed92
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#12 of 24
Median peer was paid$3.57M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,608 | $739K | |
| 2019 | 7,504 | $468K | |
| 2020 | 19,912 | $1.52M | |
| 2021 | 12,164 | $844K | |
| 2022 | 9,666 | $601K | |
| 2023 | 10,057 | $411K | |
| 2024incomplete | 5,523 | $350K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 6,782 | 5,834 | $775K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 4,182 | 3,380 | $736K |
| 80053 | Comprehensive metabolic panel | 7.6% | 8,007 | 6,489 | $373K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 1,097 | 825 | $322K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.3% | 7,582 | 5,979 | $212K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 211 | 168 | $202K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 267 | 200 | $129K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.6% | 2,163 | 1,521 | $129K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 1,745 | 1,308 | $113K |
| 84484 | 2.2% | 1,482 | 992 | $106K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 1,390 | 1,238 | $97K |
| 80061 | Lipid panel | 1.9% | 2,129 | 1,773 | $94K |
80 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.9% | 2,282 | $91K |
| 83690 | 1.8% | 1,758 | $87K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 1,583 | $87K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 8,377 | $84K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 108 | $83K |
| 0099U | 1.6% | 70 | $80K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 1,518 | $70K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 924 | $70K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 831 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 1,844 | $65K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 1,005 | $53K |
| 82248 | 1.0% | 1,345 | $51K | |
| 85027 | <1% | 1,947 | $47K | |
| 82550 | <1% | 1,127 | $45K | |
| 83605 | <1% | 1,516 | $40K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 215 | $37K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,286 | $34K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 200 | $33K |
| 83735 | <1% | 812 | $33K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 169 | $32K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 224 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 141 | $28K |
| 81003 | <1% | 862 | $26K | |
| 81001 | <1% | 1,150 | $25K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 335 | $25K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 300 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 899 | $24K |
| 82553 | <1% | 310 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,157 | $23K |
| 73630 | <1% | 249 | $19K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 488 | $18K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 353 | $15K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 164 | $13K |
| 84703 | <1% | 450 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 258 | $11K |
| J2704 | Injection, propofol, 10 mg | <1% | 132 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 339 | $10K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 98 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 215 | $8K |
| 87040 | <1% | 77 | $7K | |
| 73030 | <1% | 42 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $6K |
| 85379 | <1% | 157 | $6K | |
| 85007 | <1% | 350 | $6K | |
| 87081 | <1% | 163 | $5K | |
| 73610 | <1% | 62 | $5K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 68 | $4K |
| 73130 | <1% | 42 | $4K | |
| 74022 | <1% | 24 | $3K | |
| 85610 | <1% | 128 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 111 | $3K |
| 82150 | <1% | 57 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 47 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 47 | $2K |
| 87581 | <1% | 47 | $2K | |
| 87486 | <1% | 47 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 44 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 51 | $2K |
| 86318 | <1% | 59 | $2K | |
| 83880 | <1% | 31 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 50 | $2K |
| 87186 | <1% | 59 | $2K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 73 | $2K |
| 73564 | <1% | 15 | $1K | |
| J3490 | Unclassified drugs | <1% | 1,123 | $1K |
| 96376 | <1% | 37 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 62 | $1K |
| 87070 | <1% | 31 | $1K | |
| 87339 | <1% | 15 | $859.16 | |
| 82607 | <1% | 14 | $840.55 | |
| 87205 | <1% | 31 | $764.25 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 28 | $622.12 |
| 83540 | <1% | 25 | $620.68 | |
| 85730 | <1% | 15 | $570.52 | |
| 81025 | <1% | 22 | $295.28 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $287.46 |
| 85652 | <1% | 33 | $279.45 | |
| 86140 | <1% | 15 | $140.65 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $75.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $31.42 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKNIGHT, KIMBERLY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Braxton County Memorial Hospital | Gassaway, WV | $2.81M |
| Braxton County Memorial Hospital | Gassaway, WV | $2.21M |
| Braxton County Memorial Hospital | Gassaway, WV | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.